Literature DB >> 15101839

Levetiracetam in focal epilepsy and hepatic porphyria: a case report.

Friedemann Paul, Heinz-Joachim Meencke.   

Abstract

We report a patient with focal epilepsy and latent hereditary coproporphyria who had exacerbation of clinical symptoms of porphyria under treatment with valproate and primidone and was then treated with levetiracetam without exacerbation of clinically latent porphyria.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15101839     DOI： 10.1111/j.0013-9580.2004.00204.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN： 0013-9580            Impact factor:   5.864


  5 in total

1.  [A 25-year-old patient with colonic pseudo-obstruction, hyponatremia, hypertension, and diffuse pain].

Authors:  Philipp Lutz; Daniel Maring; Henriette J Tschampa; Tilman Sauerbruch
Journal:  Med Klin (Munich)       Date:  2010-04

Review 2.  Benefit-risk assessment of levetiracetam in the treatment of partial seizures.

Authors:  Bassel Abou-Khalil
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  Management of seizures in critically ill patients.

Authors:  Panayiotis N Varelas; Marek A Mirski
Journal:  Curr Neurol Neurosci Rep       Date:  2004-11       Impact factor: 5.081

4.  Levetiracetam in idiopathic generalised epilepsy and porphyria cutanea tarda.

Authors:  Leonilda Bilo; Roberta Meo; Maria Fulvia de Leva
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 5.  Various pharmacogenetic aspects of antiepileptic drug therapy: a review.

Authors:  Michael W Mann; Gerard Pons
Journal:  CNS Drugs       Date:  2007       Impact factor: 6.497
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.